Molecular basis of refractory constipation in childre
- Conditions
- constipationdefecation disorder1001801810017977
- Registration Number
- NL-OMON35506
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 30
Inclusion criteria for the indexpatients:
- Patients diagnosed with functional constipation not responding to maximal conservative treatment (laxatives, enemas, bowel cleansing) for at least 6 months prior to sacral neuromodulation (SNM) therapy, but responding to SNM therapy.
-Patients aged 12-18 years at time of the implantation of the sacral neuromodulator.;Inclusion Criteria for parents of indexpatients:
-Fathers and mothers of indexpatients.;Informed consent is needed for all individuals to be included. Informed consent will also be asked for by the parents as participating children will be aged 12 to 18 years.
Exclusion criteria for the indexpatients
- Patients suffering from organic pathology causing constipation.
-Patients with a history of large bowel surgery, congenital anorectal malformations or neurological disease.
-Patients not able to read and understand the written information. ;Exclusion criteria for the parents of indexpatients
-Individuals not able to read and understand the written information.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>The primary outcome is the identification of genes associated with childhood<br /><br>refractory constipation. </p><br>
- Secondary Outcome Measures
Name Time Method <p>The secondary outcome will consist of a thorough description of the clinical<br /><br>characteristics, the phenotype, of children with refractory constipation<br /><br>responding to sacral neuromodulation therapy.</p><br>